

**REMARKS**

A copy of the Notification to Comply dated August 30, 2007 is attached.

The specification has also been amended to include the attached revised Sequence Listing. The attached paper and computer readable copies of the Sequence Listing are the same. No new matter has been added.

The specification pages 6 and 7 have been amended to include sequence identifiers. The Examiner is requested to clarify the comment in the attachment to the Notification (copy attached) that pages 12, 14, 16 and 17 require sequence identifiers. Specifically, page 12 includes identifiers for SEQ ID NOs: 1 and 9. The "FEEc peptide" referred to on page 12, and elsewhere in the specification, is the "cyclic" FEE peptide. The applicants presume the Examiner is not requiring listing of a tetrapeptide "FEEC" in the Sequence Listing based on the disclosure of "the FEEc peptide" however the Examiner is requested to advise if otherwise. Page 14 similarly describes "the FEEc peptide" and "The peptide was named QDEc." Page 16 refers to "The FEEc peptide", as does page 17 of the disclosure. Clarification is requested in the event anything further is required with regard to the pages 12, 14, 16 and 17.


An early and favorable Action on the merits of the claimed invention is requested.

BOMSEL et al.  
Appl. No. 10/579,921  
October 1, 2007

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_

  
B. J. Sadoff  
Reg. No. 36,663

BJS:pp  
901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100